在转移性结肠直肠癌中添加免疫检查点抑制剂加贝瓦齐祖马布化学疗法的有效性:随机对照试验的元分析
Fumihiko Ando1,2, Akihisa Matsuda2, Yuji Miyamoto3
1Department of Cell Biology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo 113-8602, Japan.
Cancers
|August 14, 2025
概括
将免疫检查点抑制剂 (ICI) 添加到化疗和贝瓦齐祖马布中,可以改善转移性结直肠癌 (mCRC) 无进展生存率,并进行熟练的不匹配修复 (pMMR). 需要进一步的研究来证实长期的结果和好处.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 免疫检查点抑制剂 (ICI) 在熟练的不匹配修复 (pMMR) 和微卫星稳定性 (MSS) 转移性结直肠癌 (mCRC) 中表现出有限的有效性.
- 血管内皮生长因子 (VEGF) 抑制或化疗可以增强免疫性,可能提高ICI的有效性.
研究的目的:
- 评估在pMMR mCRC中添加ICI加上化疗和贝瓦齐祖马布的疗效.
- 分析无进展生存率 (PFS),总生存率 (OS),客观反应率 (ORR) 和严重不良事件 (AE).
主要方法:
- 一项对四项随机对照试验 (986名患者) 的元分析,比较化疗加贝瓦齐祖马布,有或没有ICI.
- 主要结果:PFS. 二次结局:OS,ORR,严重的副作用 (等级≥3).
- 随机效应模型被用来计算危险比率 (HRs) 和几率比率 (ORs) 以95%的置信区间 (CI).
主要成果:
- 添加ICI显著改善了PFS (HR:0.82;95%CI:0.70-0.96;p=0.01) 没有统计异质.
- 在OS或ORR中没有观察到显著差异,尽管在ICI中注意到了OS的有利趋势.
- 在接受ICI的组中,没有发现严重不良事件的显著增加.
结论:
- 将ICI添加到化疗和贝瓦齐祖马布中显示出对pMMR mCRC的PFS的潜在益处.
- 这些发现是初步的和产生假设的,需要在生物标志物驱动的试验中进行进一步的调查.
- 长期结果和ICI在这个患者群体中的确切作用需要进一步澄清.
更多相关视频
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.6K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
相关概念视频
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
